Cirius is a clinical stage biotechnology company developing MSDC-0602, a PPARī§ sparing thiazolidinedione (TZD) for non-alcoholic hepatosteatosis (NASH).
Cirius is a clinical stage biotechnology company developing MSDC-0602, a PPARī§ sparing thiazolidinedione (TZD) for non-alcoholic hepatosteatosis (NASH).